|
|
|
|
|
|
|
04.09.25 - 17:33
|
Biocodex Invests up to €30 Million in MRM Health, a Belgian Microbiome Therapy Innovator (Business Wire)
|
|
|
GENTILLY, France--(BUSINESS WIRE)--Biocodex, a French family-owned pharmaceutical pioneer in microbiota research for over 70 years, announces a strategic equity investment of €11 million in MRM Health, a Belgian clinical-stage biotech developing innovative microbiome-based therapeutics for inflammatory diseases and immune-oncology. The total partnership could reach approximately €30 million, reflecting Biocodex's long-term commitment to advancing new therapeutic approaches.
MRM Health's €55 million Series B round was led by Biocodex, with strong participation from ATHOS, new investor BNP Paribas Fortis Private Equity, and existing investors SFPIM (Belgium's sovereign wealth fund), Ackermans & van Haaren (AvH), OMX Ventures Europe (OMX), and Qbic II.
MRM Health is developing innovative treatments based on the human microbiome to address major diseases such as Inflammatory Bowel Diseases, autoimmune disorders, and certain cancers. Its lead asset, the flagship molecule MH002, has completed successfu...
|
|
|
|
|
04.09.25 - 07:06
|
MRM Health Raises €55 Million Series B to Advance Best-in-Class Microbiome-Based Biotherapeutic Product Pipeline (Business Wire)
|
|
|
Funding to support Phase 2b trial with MRM Health's lead program MH002 in ulcerative colitis and advance two additional programs to IND approval
Strategic partnership with Biocodex in biotherapeutics development and manufacturing adds significant non-dilutive funding in addition to the Series B financing
Investment fuels expansion of proprietary CORAL® platform and pipeline
GHENT, Belgium--(BUSINESS WIRE)--#Parkinson--MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced the successful closing of a €55 million (US$64 million) Series B financing round.
The round was led by French pharmaceutical group Biocodex and included strong participation from German-based ATHOS, as well as new investor BNP Paribas Fortis Private Equity and existing investors SFPIM, Ackermans & van Haaren (AvH), OMX Europe Venture Fund (OMX), Qbic II and VIB.
Validation of Leadership Position in Microbiome-Based Therapeutics
...
|
|
|
|
|
|
|
|
|
03.06.25 - 17:00
|
Neobroker: Scalable Capital erhält 155 Millionen Euro in neuer Finanzierungsrunde (Das Investment)
|
|
|
Frisches Kapital für die Expansion: Scalable Capital erhält 155 Millionen Euro und baut seine europäische Investmentplattform weiter aus.Das Münchener Fintech Scalable Capital hat eine Finanzierungsrunde über 155 Millionen Euro abgeschlossen. Angeführt wird die Investition von der belgischen Beteiligungsgesellschaft Sofina und dem europäischen Technologie-Investor Noteus Partners. An der Finanzierung beteiligten sich auch die bisherigen Investoren Balderton Capital, Tencent und HV Capital. Damit belaufen sich die Gesamtinvestitionen in das 2014 gegründete Unternehmen auf über 470 Millionen Euro. Ausbau der Plattform geplant...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
08.04.25 - 18:09
|
SoluPet Hires New COO to Support Upcoming Launch of Product for Canine Cognitive Dysfunction (Business Wire)
|
|
|
TORONTO--(BUSINESS WIRE)--SoluPet Inc. is thrilled to welcome Sara Curwen to the SoluPet Inc. team as the Fractional Chief Operations Officer. With more than 30 years experience in supply chain and operations within the food and consumer products industries, Sara brings her passion for operational excellence, enabled by establishing collaborative relationships with partners throughout the chain.
Most recently Sara was COO at Saje Natural Wellness where she gained valuable experience in blended retail and e-commerce operations optimization. Prior to that she held senior leadership positions at Sofina Foods and Weston Foods where she was known for her innovative approaches to leading teams through transformational efforts to reduce costs, improve service and manage supply chain disruptions. Sara has a Harvard MBA and a Bachelor of Mathematics from Waterloo.
“We are excited to have Sara join us as we move into our exciting launch phase of growth. SoluPet is well positioned to be the leading product in the ...
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
